Manufacturer Copay Coupons and Federal Programs: The Warning on the Card Does Not Stop the Claim

Manufacturer copay coupons can be Medicare kickbacks when a drug company knowingly uses them to induce purchases that Medicare helps pay for. The warning printed on the card and the transaction accepted by the system can tell different stories. The patient’s saving can leave taxpayers paying for a more expensive drug. If you administer a coupon program, handle pharmacy claims or manage patient assistance, you may see the gap between the federal-program exclusion and the prescriptions the manufacturer actually subsidizes.

What a Manufacturer Copay Coupon Does

A manufacturer copay coupon pays some or all of an insured patient’s immediate cost for a particular prescription drug. The support can arrive as a printed coupon, an electronic coupon, a debit card or a reimbursement paid directly to the patient after the purchase. The manufacturer can hire a coupon vendor to run the program.

At the pharmacy, the primary insurance claim goes first. It determines the patient’s copay. The coupon transaction follows and determines how much of that copay the manufacturer will cover. The patient pays any balance. A coupon can make a brand drug cheaper for the patient even when the insurer still pays more for that prescription than for an alternative.

That is the commercial incentive behind the assistance. The Office of Inspector General at the Department of Health and Human Services explains in its coupon bulletin that removing the patient’s copay can weaken the price pressure on the manufacturer. It also recognizes that assistance can help patients stay on treatment when their copays are unaffordable. Both effects matter: the patient’s immediate saving and the program’s drug bill can move in opposite directions.

Why Medicare and Medicaid Change the Question

Federal-program payment connects manufacturer assistance to the Anti-Kickback Statute. The law prohibits knowingly and deliberately paying to steer purchases that a federal health care program, including Medicare or Medicaid, may cover. Paying the patient’s share can supply that inducement even though the manufacturer never pays the prescriber. Private insurers administer Part D benefits, so the insurer’s name alone cannot settle the coverage question.

The Office of Inspector General’s September 2014 coupon bulletin addresses that federal boundary. Its accompanying study of manufacturer safeguards examined Medicare Part D specifically. The agency put responsibility on the companies offering the coupons to take appropriate steps to keep them from inducing federally paid purchases. The report adds that failing to take those steps may be evidence of intent to induce purchases paid for by federal healthcare programs.

A bill for a drug purchased through an illegal kickback is a false claim under the False Claims Act. The manufacturer can be responsible even when a pharmacy or physician sends the bill. That connection between the assistance and the government’s payment is what we examine with an insider.

What Makes a Copay Charity Independent?

An independent charity makes its assistance decisions separately from the manufacturer funding it. The Office of Inspector General’s 2005 patient-assistance bulletin describes the separation in practical terms: the donor does not control the charity, and the charity breaks the link between a manufacturer’s donation and the patient receiving help.

Assistance must disregard the donor’s interests and the patient’s choice of drug, provider or plan. The charity uses a reasonable, verifiable measure of financial need consistently. The manufacturer does not receive data that lets it match its donations to subsidized prescriptions for its own products. Those conditions put the charity’s eligibility rules, covered drugs and data transfers at the center of the question.

A disease fund can undermine that separation through its design. The agency warned about categories narrowed by symptoms, disease severity or how a drug is administered, effectively reserving assistance for a donor’s products. The name of a disease on the fund tells only part of the story. The drugs and patients it actually covers tell the rest.

Its 2014 supplemental bulletin made the donor’s position explicit: a favorable advisory opinion issued to a charity does not protect its manufacturer donors. Matching donations to assistance for the donor’s products remained a concern.

In November 2017, the Office of Inspector General withdrew a charity advisory opinion after finding that the charity supplied patient-specific data enabling donor correlation and let donors influence its disease categories. The agency explained that it relied on the facts the charity presented when seeking the opinion. What the charity described and what it actually did had diverged.

How Manufacturer Money Came Back as Medicare Revenue

The foundation cases show why the manufacturer cared which patients received assistance. A free prescription produces no drug-sale revenue. Funding a patient’s copay through a foundation can enable Medicare to pay the rest.

In its 2019 Amgen settlement announcement, the Justice Department alleged that Amgen funded Sensipar copays even though providing free drug to financially needy patients would have cost the company less. The foundation payments, the government alleged, generated Medicare claims and revenue for Amgen. The alleged choice was commercially revealing: the more expensive form of assistance produced the reimbursed sale.

A Fund Opened When the Contractor Was Ready

The government’s Novartis allegations tied patient transfers to the moment a foundation opened its fund. According to the government, the contractor managing Novartis’s free-drug program identified patients who would become eligible for Medicare. Novartis allegedly arranged for the foundation’s multiple sclerosis fund to open at six on a Friday evening, with contractor staff working overtime to submit their applications.

The alleged coordination connected the free-drug roster, the fund opening and the applications. Those are decisions a patient-services employee can recognize in the ordinary work of running the program.

The Specialty Pharmacy Closed the Information Loop

Advanced Care Scripts agreed to a civil settlement in August 2020 over its role in assistance for Teva’s Copaxone patients. The pharmacy acknowledged relaying foundation data to Teva so the manufacturer could match its payments with spending on those patients.

When funds were closed, the pharmacy sent Teva updates on eligible Medicare patients waiting for assistance. It sometimes received advance notice of Teva’s donations. Once a fund reopened, it sent a batch file consisting almost entirely of Copaxone applications, then often learned that most or all had been approved. The information traveled from waiting patients to the donor and back through the fund to approved assistance.

The Government Alleged a Return on the Donation

In its amended complaint against Regeneron, the government alleged that employees asked the Chronic Disease Fund how much money it needed for Eylea patients alone. The employees then compared that assistance with the Medicare revenue it would generate:

In that alleged calculation, the donation budget and the expected Medicare revenue appeared in the same business decision.

How Manufacturer Copay Coupon Screening Fails to Catch Federal Insurance

The Office of Inspector General’s 2014 report identified weaknesses in enrollment questions, claims edits and the visibility of coupon transactions. It also cited outside surveys in which approximately 6 percent to 7 percent of surveyed seniors reported using manufacturer coupons toward copayments for drugs purchased through their Medicare prescription plans.

An Eligibility Question Could Be Answered Again

An online question could tell a patient that federal insurance made them ineligible without preventing a different answer on another attempt. Among the coupons the agency reviewed, only 3 percent had website tracking to prevent a patient from changing the answer to obtain a coupon.

All surveyed manufacturers reported notices to beneficiaries for at least one coupon format. The notice stated the exclusion. The website’s behavior determined whether the same patient could get past it.

The Claims Edit Could Identify the Insurer but Miss the Plan

The bank identification number, or BIN, routes the claim to its payer. The Office of Inspector General found that a BIN could identify an insurance company without distinguishing its commercial plans from its Part D plans. Lists could also become inaccurate or outdated. One manufacturer described screening against BINs dedicated to Part D, leaving claims from insurers offering both kinds of coverage able to pass.

The processor control number, or PCN, helps distinguish plans within the same insurer. In the transaction structure the Office of Inspector General studied, that identifier appeared on the primary insurance claim but did not travel on the coupon claim. A vendor that also operated a claims switch had access that other coupon vendors lacked.

Benefit-stage information offered another way to identify Part D coverage, but access was limited. Date of birth was a weaker substitute: an age screen could miss younger Medicare beneficiaries with disabilities and reject older patients using commercial coverage.

The Edit Could Exist Without Anyone Checking Its Results

Only 30 percent of surveyed manufacturers reported auditing their claims edits. The report described audits that reviewed how claims were identified and rejected or examined processed and rejected coupons afterward. The operational question is whether the rule written for the vendor matches what happened to the claims.

The Primary Payer Could Miss the Coupon Entirely

The Office of Inspector General found that coupons generally traveled as secondary claims after the primary insurance claim had been processed. The coupon transaction did not go back to the primary insurer. Part D plans therefore could not identify coupon use through that transaction stream or apply their own edits to stop it.

Pharmacists could also miss electronic coupons applied automatically or debit cards used without being handed to them. Direct reimbursement was further removed: the manufacturer paid the patient after the purchase, outside the pharmacy claims system. Reviewing only what happened at the counter could leave that payment unseen.

The Office of Inspector General recommended that the Centers for Medicare & Medicaid Services work with the industry to improve enrollment verification and make coupons identifiable in claims. The agency agreed. For an insider, the valuable comparison is between the promised exclusion, the data available to enforce it and the transactions the program accepted.

Copay Accumulators and Maximizers Change Who Pays

A commercial copay accumulator changes whether manufacturer assistance counts toward the patient’s deductible and annual out-of-pocket limit. The patient can use the coupon, but the plan leaves its value out of the running total. When assistance runs out, the patient has more to pay before reaching the limit.

A federal court illustrated the effect in its September 2023 accumulator decision. In the court’s example, the manufacturer paid the same assistance either way, while the accumulator made the patient pay more and the insurer collect more.

The 2019 federal rule allowed plans to exclude assistance for a brand drug with an available, medically appropriate generic equivalent. A broader rule for 2021 let plans decide whether to count assistance, subject to state law. The court set that provision aside on September 29, 2023. The Department of Health and Human Services promised further rulemaking in October 2024. As of September 5, 2026, the replacement had not appeared, while the discarded text remained printed in the federal regulations.

A maximizer uses a different design: it sets the patient’s specialty-drug cost share around the manufacturer’s full annual assistance and treats the drug as outside essential health benefits, leaving those payments outside the annual cost-sharing limit. The plan’s benefit classification and assistance terms matter together.

We examine the plan and payment arrangement with you when assessing how the assistance operated.

What Evidence Is Needed to Prove Fraud?

The useful evidence connects who qualified, who paid, which prescription received assistance and what the manufacturer knew. We review the records you see in your work with you, from coupon eligibility rules and claims audits to foundation donation requests and patient transfers.

The cases show why those records belong together. A waiting-patient count explains a donation decision. A fund opening explains when applications arrived. A pharmacy’s confirmation shows which patients received help. We work with you to connect those decisions to the government-paid prescriptions and build the strongest case the evidence supports.

A whistleblower case, or qui tam case, under the False Claims Act can pay 15% to 30% of what the government recovers.

When the Screen and the Payments Disagree

If you know how federal patients got through a coupon screen or how a donor steered foundation assistance, speak with our whistleblower experts about the payments you can see. We build the case with you around the program’s decisions and the prescriptions they funded, and bring in pharmaceutical kickback whistleblower lawyers who understand patient-assistance arrangements. Tell us where the program’s rules and its payments diverged; we stay beside you through the case.